Senti Bio holders approve ST NewCo merger and 1-for-20 to 1-for-50 reverse split

Senti Biosciences, Inc.

Merger Agreement with ST NewCo Limited, Senti Merger Sub, Midco and Senti Biosciences approved 15,851,146 to 4,325,620; majority-of-the-minority vote 6,074,146 for.
Stockholders authorized a reverse stock split at a ratio of any whole number from 1-for-20 to 1-for-50, with the Board setting the ratio and power to abandon it.
Approved under Nasdaq Rule 5635(d) the issuance of more than 19.99% of outstanding shares upon exchange of Midco's Senior Secured Convertible Notes.
Class I directors Timothy Lu, Edward Mathers and Frances D. Schulz elected to serve until 2029; Mathers drew 4,287,567 withheld votes.
KPMG LLP ratified as auditor for FY2026 (20,133,068 for); 20,240,055 of 31,145,390 shares (64.98%) represented at the reconvened October 15, 2026 meeting.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.